---
title: 'Life Sciences Daily Summary: What Happened on November 14, 2026'
headline: Windward raises $225 million as it enters the public market
description: The EMA recommended seven medicines and 11 indication extensions, and
  issued advice on Mounjaro and oral contraceptives.
url: https://thebench.bio/news/summaries/2026-11-14
topic: all
date: '2026-11-14'
covers:
- '2026-11-14'
date_published: '2026-11-14T12:02:09Z'
date_modified: '2026-11-15T00:01:52Z'
tags:
- Funding
- Industry
sources: 4
publisher: TheBench.Bio
---

# Life Sciences Daily Summary: What Happened on November 14, 2026

**Windward raises $225 million as it enters the public market**

The EMA recommended seven medicines and 11 indication extensions, and issued advice on Mounjaro and oral contraceptives.

## Today in brief

Windward Bio Group raised $225 million through its Nasdaq IPO and a separate Sanofi investment to fund its respiratory and immunology programs. [1] [2] [3] The EMA’s medicines committee recommended marketing authorization for seven medicines and 11 indication extensions, and advised on possible effects of Mounjaro on oral contraceptive reliability. [4]

## Windward raises $225 million from IPO and Sanofi placement

Windward Bio Group raised $175 million in its Nasdaq IPO and secured another $50 million from Sanofi in a private placement. [2] [3] It priced about 10.3 million shares at $17 each. Windward stock rose 68% in after-hours trading on Friday. [1] [3]

Windward is developing drugs for asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis. [3] Its lead candidate, WIN378, blocks TSLP, a protein involved in inflammation, and is designed for dosing every six months. [3] WIN378 has entered the Phase 3 portion of a Phase 2/3 study in severe, uncontrolled asthma. The company expects preliminary results from two pivotal asthma studies in the first half of 2029. [3]

Windward expects Phase 2 COPD data for WIN378 and Phase 1 results for WIN027 in 2027. [2] [3] The company says the new funds should cover operations into the first half of 2029. [2] [3]

## EMA committee recommends seven medicines and flags Mounjaro contraception issue

At its November meeting, the EMA’s Committee for Medicinal Products for Human Use recommended marketing authorization for seven medicines, including Aumseqa for certain forms of non-small cell lung cancer and Baxfendy for inadequately controlled hypertension. [4] The committee also issued favorable opinions for the biosimilar insulins Garzulys and Donrafylix, and recommended expanding Gazyvaro’s use for some adults with systemic lupus erythematosus. [4]

The committee backed 11 indication extensions for medicines already authorized in the EU. These included pediatric use of Isturisa for Cushing’s syndrome from age six. [4] It also recommended a 100 mg dapivirine vaginal ring that can be replaced every three months rather than monthly. [4]

The committee adopted a communication for health professionals about possible effects of Mounjaro, whose active ingredient is tirzepatide, on oral contraceptive reliability. [4] The advice recommends contraception for women who could become pregnant and use Mounjaro. It also notes limited evidence on tirzepatide’s effects on oral contraceptives in women with obesity, overweight, or type 2 diabetes. [4]

## Also worth knowing

- Rezera postponed its planned offering, citing volatile market conditions. [1] [2]

## The day in numbers

- **$225 million**: Windward’s combined IPO and Sanofi private placement proceeds. [2] [3]
- **7**: Medicines for which the EMA committee recommended marketing authorization at its November meeting. [4]
- **11**: Indication extensions that received favorable opinions at the meeting. [4]

## Sources

1. [Windward prices IPO, Rezera postpones its offering: Finance Report](<https://www.biocentury.com/article/661604/windward-prices-ipo-rezera-postpones-its-offering-finance-report?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-14
2. [Windward raises $175M in IPO, adds $50M from Sanofi](<https://european-biotechnology.com/latest-news/windward-raises-175m-in-ipo-adds-50m-from-sanofi/>), European Biotechnology, 2026-11-13
3. [Windward Bio’s Stock Market Debut Reels In $225M for Better Biologic Drugs](<https://medcitynews.com/2026/11/windward-bio-ipo-long-acting-antibody-tslp-asthma-copd-atopic-dermatitis-wwb/>), MedCity News, 2026-11-13
4. [Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026](<https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026>), EMA Press, 2026-11-13

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661604/windward-prices-ipo-rezera-postpones-its-offering-finance-report?utm_source=bc_rss&utm_medium=rss>
[2]: <https://european-biotechnology.com/latest-news/windward-raises-175m-in-ipo-adds-50m-from-sanofi/>
[3]: <https://medcitynews.com/2026/11/windward-bio-ipo-long-acting-antibody-tslp-asthma-copd-atopic-dermatitis-wwb/>
[4]: <https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026>
